MetaVia Inc. presented late-breaking data from its obesity and metabolic disease portfolio at the ADA 2026 Scientific Sessions. The Phase 1 results for DA-1726 showed a 9.1% body weight reduction at Day 54, while preclinical studies for vanoglipel demonstrated significant weight loss and hepatoprotective effects in combination treatments.
